Vinflunine ditartrate, a fluorinated microtubule inhibitor and member of the Vinca alkaloids family, exhibits anti-angiogenic, vascular-disrupting, and anti-metastatic properties. It presents a potential avenue for studying transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and breast carcinoma[1][2].

Vinflunine (0.01-10 μM; 45 min) rapidly alters endothelial cell morphology, causing retraction and rounding[2]. Within 1 hour at the same concentrations, it disrupts capillary-like structure formation and inhibits motility, with an IC50 of 0.71 μM[2]. Over 1 to 72 hours, Vinflunine (0.001-10 μM) effectively suppresses endothelial cell proliferation in vitro[2].

Vinflunine (0.08-20 mg/kg; i.v.) reduces the number of experimental liver metastases by human LS174T colon cancer cells. Vinflunine (0.63-5 mg/kg; i.v. before and 2 days after Matrigel implantation) inhibits the bFGF-induced angiogenic response in mice in a dose-dependent manner. [Animal Model: Female athymic nude mice (BALB/c/Ola/Hsd-nu) implanted with LS174T cells][2].